for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vertex Pharmaceuticals Incorporated

VRTX.O

Latest Trade

191.06USD

Change

7.53(+4.10%)

Volume

4,442,480

Today's Range

186.19

 - 

194.75

52 Week Range

151.80

 - 

195.81

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
183.53
Open
186.91
Volume
4,442,480
3M AVG Volume
25.17
Today's High
194.75
Today's Low
186.19
52 Week High
195.81
52 Week Low
151.80
Shares Out (MIL)
257.04
Market Cap (MIL)
45,297.36
Forward P/E
38.36
Dividend (Yield %)
--

Next Event

Q3 2019 Vertex Pharmaceuticals Inc Earnings Release

Latest Developments

More

Vertex Pharma Establishes Wholesale Acquisition Cost For Trikafta Of $311,503 On An Annual Basis

FDA Approves TRIKAFTA To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older Who Have At Least One F508del Mutation

FDA Approves New Breakthrough Therapy For Cystic Fibrosis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry

Biotechnology & Drugs

Contact Info

50 Northern Ave

+1.617.3416393

https://www.vrtx.com/

Executive Leadership

Jeffrey M. Leiden

Chairman of the Board, President, Chief Executive Officer

Charles F. Wagner

Chief Financial Officer, Executive Vice President

Michael J. Parini

Executive Vice President, Chief Legal and Administrative Officer

David Altshuler

Executive Vice President - Global Research, Chief Scientific Officer

Stuart A. Arbuckle

Executive Vice President, Chief Commercial Officer

Key Stats

1.96 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.7K

2017

2.2K

2018

3.0K

2019(E)

3.7K
EPS (USD)

2016

0.850

2017

1.950

2018

4.080

2019(E)

4.594
Price To Earnings (TTM)
69.95
Price To Sales (TTM)
13.11
Price To Book (MRQ)
8.92
Price To Cash Flow (TTM)
62.70
Total Debt To Equity (MRQ)
11.61
LT Debt To Equity (MRQ)
10.88
Return on Investment (TTM)
13.76
Return on Equity (TTM)
11.08

Latest News

Latest News

Vertex prices cystic fibrosis combo treatment at $311,000-per-year

Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis (CF) at $311,503 per year, after winning early U.S. approval on Monday.

FDA approves Vertex Pharma's combo treatment for cystic fibrosis

The U.S. Food and Drug Administration approved Vertex Pharmaceuticals Inc's combination treatment for a rare condition called cystic fibrosis, the agency said on Monday.

Vertex to buy cell therapy developer Semma for $950 million

Vertex Pharmaceuticals Inc <VRTX.O> said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash with an aim to develop potentially curative stem-cell based treatments for diabetes.

Vertex to buy cell therapy developer Semma for $950 mln

Vertex Pharmaceuticals Inc said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash to develop stem-cell based treatments for diabetes.

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments...

Vertex to file for approval of cystic fibrosis therapy in 2019

Vertex Pharmaceuticals Inc said on Thursday it will apply for regulatory approval later this year for its triple combination of drugs to treat life-shortening genetic condition cystic fibrosis.

BRIEF-Cincor Pharma Closes $50 Mln Series A Financing

* CINCOR PHARMA IN-LICENSES ALDOSTERONE SYNTHASE INHIBITOR, CIN-107, AND CLOSES $50 MILLION SERIES A FINANCING

BRIEF-Crispr Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For Treatment Of Beta Thalassemia

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF BETA THALASSEMIA Source text for Eikon: Further company coverage:

Vertex cystic fibrosis triple combo therapy succeeds in important trials

Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening...

Vertex Pharma boots out COO for 'personal behavior' violations

Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct.

Vertex Pharma terminates interim CFO's employment for code violations

Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing personal behavior that violated its code of conduct.

Vertex posts positive data from cystic fibrosis triple combo trials

Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.

Vertex cystic fibrosis drug gets expanded approval for use in infants

U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months.

Vertex Pharma profit tops estimates on strong launch of new CF drug

Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.

BRIEF-Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor

* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

CORRECTED-Vertex Pharma's quarterly profit falls 15.1 percent

Vertex Pharmaceuticals Inc's quarterly profit fell 15.1 percent, hurt by higher research and development spending.

BRIEF-Vertex Pharmaceuticals Inc Reports Qtrly EPS Of $0.81

* COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION

BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage:

BRIEF-Veritas Pharma Enters Into Share Purchase Agreement With 3 Carbon Extractions Inc.

* VERITAS PHARMA ENTERS INTO SHARE PURCHASE AGREEMENT WITH 3 CARBON EXTRACTIONS INC. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Vertex Pharmaceuticals CEO Leiden's 2017 Compensation Was $17.2 Mln

* VERTEX PHARMACEUTICALS INC - CEO JEFFREY LEIDEN'S 2017 TOTAL COMPENSATION WAS $17.2 MLN VS $17.4 MLN IN 2016 - SEC FILING Source text - https://bit.ly/2uQs5Cx Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up